20102020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2020

Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes

Prakoso, D., De Blasio, M. J., Tate, M., Kiriazis, H., Donner, D. G., Qian, H., Nash, D., Deo, M., Weeks, K. L., Parry, L. J., Gregorevic, P., McMullen, J. R. & Ritchie, R. H., Apr 2020, In : American Journal of Physiology - Heart and Circulatory Physiology. 318, 4, p. H840-H852 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
1 Citation (Scopus)
2017

Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction

Prakoso, D., De Blasio, M. J., Qin, C., Rosli, S., Kiriazis, H., Qian, H., Du, X-J., Weeks, K. L., Gregorevic, P., McMullen, J. R. & Ritchie, R. H., 7 Jun 2017, In : Clinical Science. 131, 12, p. 1345-1360 16 p.

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)
2015

Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets

Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L. & McMullen, J. R., 2015, In : Archives of Toxicology. 89, 9, p. 1401 - 1438 38 p.

Research output: Contribution to journalArticleResearchpeer-review

174 Citations (Scopus)
2012

Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin

Winbanks, C. E., Weeks, K. L., Thomson, R. E., Sepulveda, P. V., Beyer, C., Qian, H., Chen, J. L., Allen, J. M., Lancaster, G. I., Febbraio, M. A., Harrison, C. A., McMullen, J. R., Chamberlain, J. S. & Gregorevic, P., 28 Jun 2012, In : Journal of Cell Biology. 197, 7, p. 997-1008 12 p.

Research output: Contribution to journalArticleResearchpeer-review

95 Citations (Scopus)

Phosphoinositide 3-kinase p110{alpha} is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction

Weeks, K. L., Gao, X-M., Du, X-J., Boey, E. JH., Matsumoto, A., Bernardo, B. C., Kiriazis, H., Cemerlang, N., Tan, J. W., Tham, Y. K., Franke, T. F., Qian, H., Bogoyevitch, M. A., Woodcock, E. A., Febbraio, M. A., Gregorevic, P. & McMullen, J. R., 2012, In : Circulation: Heart Failure. 5, 4, p. 523 - 534 12 p.

Research output: Contribution to journalArticleResearchpeer-review

64 Citations (Scopus)
2010

Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies

Bernardo, B. C., Weeks, K. L., Pretorius, L. & McMullen, J. R., 2010, In : Pharmacology and Therapeutics. 128, 1, p. 191 - 227 37 p.

Research output: Contribution to journalArticleResearchpeer-review

447 Citations (Scopus)

PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA

Lin, R. CY., Weeks, K. L., Gao, X-M., Williams, R. BH., Bernardo, B. C., Kiriazis, H., Matthews, V., Woodcock, E. A., Bouwman, R., Mollica, J., Speirs, H. J., Dawes, I. W., Daly, R. J., Shioi, T., Izumo, S., Febbraio, M. A., Du, X-J. & McMullen, J. R., 2010, In : Arteriosclerosis, Thrombosis and Vascular Biology. 30, 4, p. 724 - 732 9 p.

Research output: Contribution to journalArticleResearchpeer-review

115 Citations (Scopus)